Christopher P. Venner

6.3k citations

102 papers · 1.6k indexed · h-index 16

Impact in

Hematology top 2%
- Multiple Myeloma Research and Treatments
Nephrology top 2%
- Parathyroid Disorders and Treatments

Papers in

Hematology 72
- Multiple Myeloma Research and Treatments 68
- Acute Myeloid Leukemia Research 6
Oncology 48
- Cancer Treatment and Pharmacology 25
- Peptidase Inhibition and Analysis 15

Co-authors: Ashutosh Wechalekar Helen J. Lachmann Philip N. Hawkins Julian D. Gillmore Simon Gibbs Carol Whelan Jennifer H. Pinney Sanjay M Banypersad
Journals: Blood (40 papers)Journal of Clinical Oncology (9 papers)British Journal of Haematology (5 papers)Haematologica (4 papers)European Journal Of Haematology (4 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Christopher P. Venner

85 papers receiving 1.6k citations

Peers

Countries citing papers authored by Christopher P. Venner

Since Specialization

Citations

This map shows the geographic impact of Christopher P. Venner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Venner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Venner more than expected).

Fields of papers citing papers by Christopher P. Venner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher P. Venner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Venner. The network helps show where Christopher P. Venner may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Christopher P. Venner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher P. Venner Line = papers co-authored together Christopher P. Venner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy of Daratumumab-Bortezomib-Lenalidomide-Dexamethasone (DVRd) vs Daratumumab-Lenalidomide-Dexamethasone (DRd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Clinical Lymphoma Myeloma & Leukemia ·Saad Z. Usmani, Thierry Façon, Vânia Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Jianming He, Sandhya Nair, Hana Nazal, Eric M. Ammann, Y. Liu, H. Siedentopf, Sonja Zweegman	2025	0
2	Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database Transplantation and Cellular Therapy ·Christopher P. Venner, Peter Duggan, Kevin Song, Donna Reece, Smriti Sharma, Jiandong Su, Víctor H. Jiménez‐Zepeda, Arleigh McCurdy, Martha Louzada, Hira Mian, Michaël Sébag, Darrell White, Julie Stakiw, Rami Kotb, A. J. Mayell, Tony Reiman, Dawn Wei Li. Lim, Michael P. Chu, Willian Estanley Cubías Gutierrez, Richard LeBlanc	2024	1
3	Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis Blood Advances ·John R. Speed, Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin, Christopher P. Venner, Irwindeep Sandhu, Arleigh McCurdy, Thierry Façon, María‐Victoria Mateos, Hira Mian	2024	8
4	Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database Blood ·Arleigh McCurdy, Dawn Wei Li. Lim, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Víctor H. Jiménez‐Zepeda, Kevin Song, Hira Mian, Michaël Sébag, Willian Estanley Cubías Gutierrez, Julie Stakiw, Tony Reiman, Rami Kotb, A. J. Mayell, Rayan Kaedbey, Martha Louzada, Richard LeBlanc	2023	1
5	Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis Leukemia & lymphoma ·A Améri, Alina S. Gerrie, Kerry J. Savage, Diego Villa, David W. Scott, Jeffrey W. Craig, Pedro Farinha, Brian Skinnider, Graham W. Slack, Joseph M. Connors, Laurie H. Sehn, Christopher P. Venner, Ciara L. Freeman	2023	2
6	Exploring participant perceptions of a virtually supported home exercise program for people with multiple myeloma using a novel eHealth application: a qualitative study Supportive Care in Cancer ·Sheka Y Aloyouni, Frances Sobierajski, Kendal Angell, A. DiCintio, Christopher P. Venner, Puneeta Tandon, Margaret L. McNeely	2023	2
7	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group Amyloid ·Ashutosh Wechalekar, María Teresa Cibeira, Simon Gibbs, Arnaud Jaccard, Shaji Kumar, Giampaolo Merlini, Giovanni Palladini, Vaishali Sanchorawala, Stefan Schönland, Christopher P. Venner, Mario Boccadoro, Efstathios Kastritis	2022	46
8	Filgrastim-Induced Bone Pain Is More Prevalent and Severe during Stem Cell Mobilization Transplantation and Cellular Therapy ·Matthew Anaka, Veronika Anna Rojek-Wöckner, S. Turgeon, Anthea Peters, Ann Beirne, Christopher P. Venner, Irwindeep Sandhu, Michael P. Chu	2021	0
9	Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism Current Issues in Molecular Biology ·Rutter Jeremy B., Yassir Ali, Jing Li, Christopher P. Venner, Irwindeep Sandhu, Anthea Peters, Afsaneh Lavasanifar, Raymond Lai	2021	4
10	The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada Journal of Cardiac Failure ·Nariman Sepehrvand, Erik Youngson, Nowell M. Fine, Christopher P. Venner, D. Ian Paterson, Jeffrey A. Bakal, Cynthia M. Westerhout, Finlay A. McAlister, Padma Kaul, Justin A. Ezekowitz	2021	5
11	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model Cancers ·Rutter Jeremy B., Ommoleila Molavi, Abdulraheem Alshareef, Magdalena Reiter, Qian Wang, Michael P. Chu, Christopher P. Venner, Irwindeep Sandhu, Anthea Peters, Afsaneh Lavasanifar, Raymond Lai	2018	20
12	Cardiac Rehabilitation in Patients With Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Cardio-oncology Pilot Project Canadian Journal of Cardiology ·Kursad Ozbay, Bruno G. Van Hemelryck, อภิรดี สรวิสูตร, Christopher P. Venner, D. Ian Paterson, Gábor Gyenes, Edith Pituskin	2018	12
13	A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma Blood ·Darrell White, Nizar J. Bahlis, Christopher P. Venner, Gary J. Schiller, Cristina Gasparetto, Heather J. Sutherland, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, William Bensinger, Brea Lipe, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Richard LeBlanc	2017	4
14	Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM) Blood ·Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Gary J. Schiller, Richard LeBlanc, William Bensinger, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Christine I. Chen	2017	0
15	A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs) Blood ·Cristina Gasparetto, Suzanne Lentzsch, Gary J. Schiller, William Bensinger, Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Rami Kotb, Christopher P. Venner, Richard LeBlanc, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Brea Lipe	2017	2
16	Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure Blood ·Christine I. Chen, Heather J. Sutherland, Rami Kotb, Michaël Sébag, Darrell White, William Bensinger, Cristina Gasparetto, Richard LeBlanc, Christopher P. Venner, Suzanne Lentzsch, Gary J. Schiller, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Nizar J. Bahlis	2017	3
17	The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data Blood ·Eric A. Buchanan, Irwindeep Sandhu, Michael P. Chu, Georges Bucyibaruta, Ismail Ismail, Andrew R. Belch, Linda M. Pilarski, 戸谷誠之, Christopher P. Venner	2017	2
18	The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort Blood ·أحمد جاسم حميد, Víctor H. Jiménez‐Zepeda, Nizar J. Bahlis, Paola Neri, Irwindeep Sandhu, Michael P. Chu, Ismail Ismail, Jason Tay, Peter Duggan, Andrew Belch, Georges Bucyibaruta, Linda M. Pilarski, 戸谷誠之, Christopher P. Venner	2017	1
19	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study The Lancet Haematology ·Shameem Mahmood, Frank Bridoux, Christopher P. Venner, Sajitha Sachchithanantham, Janet A. Gilbertson, Dorota Rowczenio, Thomas Wagner, Rabya Sayed, Ketna Patel, Marianna Fontana, Carol Whelan, Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore, Ashutosh Wechalekar	2015	95
20	Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival Blood ·Christopher P. Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon Gibbs, Jennifer H. Pinney, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar	2012	197

About Christopher P. Venner

Christopher P. Venner is a scholar working on Hematology, Oncology, Genetics, Nephrology and Molecular Biology, having authored 102 papers that have together received 1.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (68 papers), Protein Degradation and Inhibitors (37 papers), Cancer Treatment and Pharmacology (25 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (19 papers), Peptidase Inhibition and Analysis (15 papers), Chronic Lymphocytic Leukemia Research (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Acute Myeloid Leukemia Research (6 papers). The work is most often cited by research in Hematology (514 citations), Nephrology (323 citations), Genetics (286 citations), Molecular Biology (1.4k citations) and Oncology (485 citations). Christopher P. Venner has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Ashutosh Wechalekar, Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore, Simon Gibbs, Carol Whelan, Jennifer H. Pinney, Sanjay M Banypersad, Jason Dungu and Janet A. Gilbertson. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Haematologica and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact